1. Home
  2. ixekizumab

Tags : ixekizumab

Eli Lilly to Present Data of Taltz (ixekizumab) for Patients with Psoriatic Arthritis at EULAR 2020 #EULAR

Eli Lilly to Present Data of Taltz (ixekizumab) for Patients

Tuba Khan June 3, 2020

Shots: Eli Lilly shared new results from a subgroup analysis of the P-IIIb/IV, 52-wks. SPIRIT-H2H study assessing Taltz vs Humira (adalimumab) in biologic-naïve patients with active PsA with 1EPs as ACR50 & PASI 100 @24wks. The study compares Taltz and Humira in subgroups of patients on monothx./ concomitant MTX/ concomitant MTX along with csDMARD including […]Read More

Eli Lilly’s Taltz (ixekizumab) Receives the US FDA’s Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Eli Lilly’s Taltz (ixekizumab) Receives the US FDA’s Approval for

Tuba Khan March 30, 2020

Shots: The approval is based on P-III study assessing Taltz (20mg for <25kg/40mg for 25-50kg/80 mg for >50 kg @12wks., with 40/80/160mg starting doses, respectively) vs PBO in 171 patients aged 6-18 yrs. with mod. to sev. PsO who are candidates for systemic therapy or phototherapy The P-III study results: patients achieving PASI 75 (89% […]Read More

Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)

Eli Lilly’s Taltz (ixekizumab) Receives Third US FDA’s Approval for

Tuba Khan August 27, 2019

Shots: The approval is based on two P-III studies assessing Taltz vs PBO in 657 patients with active AS, randomized into two groups i.e, COAST-V in patients who are bDMARD-naïve and COAST-W in patients who are intolerant or have an inadequate response to TNF inhibitors The two P-III study results: patients achieved ASAS40 @16wks. COAST-V […]Read More

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in P-IIIb/IV SPIRIT-H2H Study for Active Psoriatic Arthritis #EULAR2019

Eli Lilly to Report Positive Results of Taltz (ixekizumab) in

Tuba Khan June 14, 2019

Shots: The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks. The P-IIIb/IV SPIRIT-H2H study results: met its 1EPs & 2Eps i.e, @24wks. reduction by 50% in disease activity as defined by ACR50; PASI100 (36% vs 28%) & superior to Humira, ACR50 […]Read More

Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years P-III Study for Plaque Psoriasis #WCD2019

Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years

Tuba Khan June 11, 2019

Shots: The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1 Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%), presented at WCD with additional data of UNCOVER-3 study […]Read More

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study

Tuba Khan April 23, 2019

Shots: The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks. The P-III COAST-X study results:  @16 & 52wks. met its 1Eps & 2Eps; improvement in the signs and symptoms of nr-axSpA; improvement in ASDAS & BASDAI; […]Read More

Copyright ©2020 PharmaShots | Powered by Octavus Consulting